Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2016 1
2020 3
2021 3
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Malignant Peripheral Nerve Sheath Tumor"
Page 1
Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R. Brown R. Curr Oncol Rep. 2023 Dec;25(12):1409-1417. doi: 10.1007/s11912-023-01451-z. Epub 2023 Oct 31. Curr Oncol Rep. 2023. PMID: 37906356 Review.
Neurofibromatosis type I (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis represent a diverse group of genetic tumor predisposition syndromes with a shared feature of tumors affecting the peripheral nerve sheaths. ...This article provides an update …
Neurofibromatosis type I (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis represent a diverse group of genetic tumor predis …
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.
Akshintala S, Mallory NC, Lu Y, Ballman KV, Schuetze SM, Chugh R, Maki RG, Reinke DK, Widemann BC, Kim A. Akshintala S, et al. Oncologist. 2023 May 8;28(5):453-459. doi: 10.1093/oncolo/oyac272. Oncologist. 2023. PMID: 36724001 Free PMC article. Clinical Trial.
BACKGROUND: Evaluation of prior phase II trials for malignant peripheral nerve sheath tumors (MPNST) may help develop more suitable trial endpoints in future studies. ...In comparison, on the SARC006 trial the PFS rate at 4 months was 94% …
BACKGROUND: Evaluation of prior phase II trials for malignant peripheral nerve sheath tumors (MPNST) may help de …
Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
Butler E, Schwettmann B, Geboers S, Hao G, Kim J, Nham K, Sun X, Laetsch TW, Xu L, Williams NS, Skapek SX. Butler E, et al. Pediatr Blood Cancer. 2020 Dec;67(12):e28639. doi: 10.1002/pbc.28639. Epub 2020 Sep 25. Pediatr Blood Cancer. 2020. PMID: 32975370
BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive form of soft-tissue sarcoma (STS) in children. Despite intensive therapy, relatively few children with metastatic and unresectable disease survive beyond three y …
BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive form of soft-tissue sarcoma …
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
Nishida Y, Urakawa H, Nakayama R, Kobayashi E, Ozaki T, Ae K, Matsumoto Y, Tsuchiya H, Goto T, Hiraga H, Naka N, Takahashi S, Ando Y, Ando M, Kuwatsuka Y, Hamada S, Ueda T, Kawai A. Nishida Y, et al. Int J Cancer. 2021 Jan 1;148(1):140-149. doi: 10.1002/ijc.33201. Epub 2020 Aug 3. Int J Cancer. 2021. PMID: 32638374 Free article. Clinical Trial.
Malignant peripheral nerve sheath tumor (MPNST) often does not respond well to chemotherapy and develops against a background of NF1. The purpose of our study was to examine the efficacy of pazopanib against MPNST. Our study was designed as a ph …
Malignant peripheral nerve sheath tumor (MPNST) often does not respond well to chemotherapy and develops …
Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group.
Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Sotti G, Treuner J. Carli M, et al. J Clin Oncol. 2005 Nov 20;23(33):8422-30. doi: 10.1200/JCO.2005.01.4886. J Clin Oncol. 2005. PMID: 16293873 Clinical Trial.
PURPOSE: To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath tumors (MPNSTs) and to identify risk factors associated with outcome. ...Postoperative radiotherapy may have a role in improving local cont …
PURPOSE: To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath …
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B. Varin J, et al. Oncotarget. 2016 Jun 14;7(24):35753-35767. doi: 10.18632/oncotarget.7099. Oncotarget. 2016. PMID: 26840085 Free PMC article.
Approximately 30-50% of individuals with Neurofibromatosis type 1 develop benign peripheral nerve sheath tumors, called plexiform neurofibromas (PNFs). PNFs can undergo malignant transformation to highly metastatic malignant peripheral …
Approximately 30-50% of individuals with Neurofibromatosis type 1 develop benign peripheral nerve sheath tumors, called …
An Analysis of 20 Cases of Radiation-Associated Sarcoma, Including 4 Cases Treated by Carbon Ion Radiotherapy.
Negishi T, Matsunobu A, Endo M, Yokoyama R, Kusano S, Furubayashi N, Taguchi K, Shioyama Y, Iida K, Fujiwara T, Setsu N, Matsumoto Y, Nakashima Y, Kohashi K, Yamamoto H, Oda Y, Nakamura M. Negishi T, et al. Oncology. 2022;100(3):148-154. doi: 10.1159/000521504. Epub 2021 Dec 16. Oncology. 2022. PMID: 34915507
The histological diagnoses of RAS included osteosarcoma (n = 8), leiomyosarcoma (n = 3), undifferentiated pleomorphic sarcoma (n = 3), rhabdomyosarcoma (n = 1), angiosarcoma (n = 1), malignant peripheral nerve sheath tumor (n = 1), spindle cell …
The histological diagnoses of RAS included osteosarcoma (n = 8), leiomyosarcoma (n = 3), undifferentiated pleomorphic sarcoma (n = 3), rhabd …
Carbon ion radiotherapy for unresectable retroperitoneal sarcomas.
Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, Tsuji H, Ito H, Tsujii H. Serizawa I, et al. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1105-10. doi: 10.1016/j.ijrobp.2008.12.019. Epub 2009 May 23. Int J Radiat Oncol Biol Phys. 2009. PMID: 19467578
PURPOSE: To evaluate the applicability of carbon ion radiotherapy (CIRT) for unresectable retroperitoneal sarcomas with regard to normal tissue morbidity and local tumor control. ...Of the patients, 16 had primary disease and 8 recurrent disease. Histologic diagnose …
PURPOSE: To evaluate the applicability of carbon ion radiotherapy (CIRT) for unresectable retroperitoneal sarcomas with regard to nor …
A Case of Inv(1)(q23q31) TPR-NTRK1 Fusion-Positive Spindle Cell Neoplasm in an Infant-Uncovered by Next-Generation Sequencing: Diagnostic Challenge, Review, and Therapeutic Implications.
Rekhi B, Shetty O, Bapat P, Gurav M, Qureshi S. Rekhi B, et al. Int J Surg Pathol. 2021 Feb;29(1):102-108. doi: 10.1177/1066896920927467. Epub 2020 Jun 3. Int J Surg Pathol. 2021. PMID: 32489127
Lately, NTRK-positive mesenchymal tumors are being increasingly identified, mostly in pediatric patients, in view of associated treatment implications, especially in recurrent and unresectable tumors. A 1-year-old male child presented with a rapidly growing tumor ma …
Lately, NTRK-positive mesenchymal tumors are being increasingly identified, mostly in pediatric patients, in view of associated treatment im …